Alliance for Wellness Inc — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$1,218	1
2024	Research	$23,935	2
2023	Research	$45,206	50
2022	Research	$23,389	22
2021	Research	$362,305	156
2020	Research	$330,789	56
2019	Research	$94,017	6

Breakdown

Who paid Research payments · program years 2019–2025

Teva Pharmaceuticals USA, Inc. $503,935 37 payments
Takeda Pharmaceuticals U.S.A., Inc. $244,423 242 payments
H. Lundbeck A S $70,503 10 payments
Biogen, Inc. $60,293 3 payments
Pfizer Inc. $1,706 1 payment

Studies the money was for Research payments · program years 2019–2025

A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia $503,935 37 payments
A Phase 4, Multicenter, 2-Part Study Composed of A 1-Year Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Comparator, Dose-Optimization Evaluation Followed By A 1-Year Open-Label Evaluation to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged-Release (Spd503) in Children and Adolescents Aged 6 to 17 Years With Attention-Deficit/Hyperactivity Disorder $198,956 205 payments
Active Reference (Fluoxetine) Fixed-Dose Study of Vortioxetine in Pediatric Patients Aged 7 to 11 Years With Major Depressive Disorder (MDD) $70,503 10 payments
A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) $60,293 3 payments
A Phase 4, Multicenter, 2-Part Study Composed of A 1-Year Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Comparator, Dose-Optimization Evaluation Followed By A 1-Year Open-Label Evaluation to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged-Release (Spd503) in Children and Adolescents Aged 6 to 17 Years With Attention-Deficit/Hyperactivity Disorder $45,467 37 payments
A Phase 3 Multicenter Fourweek Randomized Doubleblind Placebocontrolled Parallelgroup Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I Disorder Current Or Most Recent Episode Manic $1,706 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.